Vera Belgers

Mrs. Vera Belgers


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2020 in Journal of Neuro-Oncology
Verified
Journal Article
Open access
PDF file
VBVera Belgers
Vera Belgers
TNTianne Numan
Tianne Numan
SKShanna D. Kulik
Shanna D. Kulik
AHArjan Hillebrand
Arjan Hillebrand
PHPhilip C. de Witt Hamer
Philip C. de Witt Hamer
LDLinda Douw
Linda Douw
Introduction: Progression-free survival (PFS) in glioma patients varies widely, even when stratifying for known predictors (i.e. age, molecular tumor subtype, presence of epilepsy, tumor grade and Karnofsky performance status). Neuronal activity has been shown to accelerate tumor growth in an animal model, suggesting that brain activity may be valuable as a PFS predictor. We investigated whether postoperative oscillatory brain activity, assessed by resting-state magnetoencephalography is of additional value when predicting PFS in glioma patients. Methods: We included 27 patients with grade II–IV gliomas. Each patient’s oscillatory brain activity was estimated by calculating broadband power (0.5–48 Hz) in 56 epochs of 3.27 s and averaged over 78 cortical regions of the Automated Anatomical Labeling atlas. Cox proportional hazard analysis was performed to test the predictive value of broadband power towards PFS, adjusting for known predictors by backward elimination. Results: Higher broadband power predicted shorter PFS after adjusting for known prognostic factors (n = 27; HR 2.56 (95% confidence interval (CI) 1.15–5.70); p = 0.022). Post-hoc univariate analysis showed that higher broadband power also predicted shorter overall survival (OS; n = 38; HR 1.88 (95% CI 1.00–3.54); p = 0.038). Conclusions: Our findings suggest that postoperative broadband power is of additional value in predicting PFS beyond already known predictors.

1 February 2023 in Cannabis & Cannabinoid Research
Verified
Journal Article
Open access
VBVera Belgers
Vera Belgers
JRJantine G. Röttgering
Jantine G. Röttgering
LDLinda Douw
Linda Douw
MKMartin Klein
Martin Klein
JKJohannes C.F. Ket
Johannes C.F. Ket
PHPhilip C. de Witt Hamer
Philip C. de Witt Hamer
Background: Cannabinoids have been suggested to alleviate frequently experienced symptoms of reduced mental well-being such as anxiety and depression. Mental well-being is an important subdomain of health-related quality of life (HRQoL). Reducing symptoms and maintaining HRQoL are particularly important in malignant primary brain tumor patients, as treatment options are often noncurative and prognosis remains poor. These patients frequently report unprescribed cannabinoid use, presumably for symptom relieve. As studies on brain tumor patients specifically are lacking, we performed a meta-analysis of the current evidence on cannabinoid efficacy on HRQoL and mental well-being in oncological and neurological patients. Methods: We performed a systematic PubMed, PsychINFO, Embase, and Web of Science search according to PRISMA guidelines on August 2 and 3, 2021. We included randomized controlled trials (RCTs) that assessed the effects of tetrahydrocannabinol (THC) or cannabidiol (CBD) on general HRQoL and mental well-being. Pooled effect sizes were calculated using Hedges g. Risk of bias of included studies was assessed using Cochrane's Risk of Bias tool. Results: We included 17 studies: 4 in oncology and 13 in central nervous system (CNS) disease. Meta-analysis showed no effect of cannabinoids on general HRQoL ( g =−0.02 confidence interval [95% CI −0.11 to 0.06]; p =0.57) or mental well-being ( g =−0.02 [95% CI −0.16 to 0.13]; p =0.81). Conclusions: RCTs in patients with cancer or CNS disease showed no effect of cannabinoids on HRQoL or mental well-being. However, studies were clinically heterogeneous and since many glioma patients currently frequently use cannabinoids, future studies are necessary to evaluate its value in this specific population.

26 January 2023 in Heliyon
Verified
Journal Article
Open access
JRJantine G. Röttgering
Jantine G. Röttgering
VBVera Belgers
Vera Belgers
MKMathilde Cornelia Maria Kouwenhoven
Mathilde Cornelia Maria Kouwenhoven
MSMaaike Schuur
Maaike Schuur
TPTjeerd J. Postma
Tjeerd J. Postma
MKMartin Klein
Martin Klein
Glioma patients experience a multitude of symptoms that negatively affect their health-related quality of life. Symptoms vary greatly across disease phases, and the patients' stable phase might be particularly suitable for assessing and treating symptoms. Identifying symptoms and patients' needs is a first step toward improving patient care. In glioma patients with stable disease, we assessed the frequency and burden of patient-reported symptoms, examined how these symptoms co-occur, and also determined whether patients would consider treatment to ameliorate specific symptoms. In this retrospective study, patients rated the frequency and burden of seventeen symptoms on a seven-point Likert scale and stated whether they would consider treatment for these symptoms. Correlations between frequency, burden, and considering treatment were evaluated with Kendall's Tau correlation coefficients. Based on partial correlations between symptom frequencies we visualized the symptoms as a network. Fifty-two glioma patients with stable disease were included (31 WHO grade II/III, 21 WHO grade IV). The top five symptoms were fatigue, memory problems, reduced physical fitness, concentration problems, and drowsiness. Fatigue had the highest median frequency (4.5, interquartile range 2.5). Over half of the patients experienced three or more symptoms simultaneously and associations between all symptoms were depicted as a network. Overall, 35% of patients would consider treatment for at least one symptom. The wish to undergo symptom treatment correlated only moderately with symptom frequency and burden (range of correlations 0.24-0.57 and 0.28-0.61, respectively). Glioma patients with stable disease experience multiple symptoms with a consequently high symptom burden. Despite the high prevalence of symptoms, the inclination for symptom management interventions was relatively low. The most frequent and burdensome symptoms and the way they are interrelated could serve as a roadmap for future research on symptom management in these patients.

11 July 2024 in Nature Mental Health
Verified
Journal Article
Open access
PDF file
MGMaisa N. G. van Genderen
Maisa N. G. van Genderen
VBVera Belgers
Vera Belgers
JNJohanna M. Niers
Johanna M. Niers
LDLinda Douw
Linda Douw
JRJantine G. Röttgering
Jantine G. Röttgering
AAA A
A A
Gliomas are primary brain tumors that can cause neuropsychiatric symptoms, including severe depressive symptoms (SDS; in 14%) and an absence of depressive symptoms (ADS; in 29%), determined by Center for Epidemiologic Studies Depression (CES-D) scores. We examined the association between both SDS and ADS and brain tumor location in 201 patients with diffuse glioma before surgery. Tumors and white matter disconnectomes did not relate to CES-D using sparse canonical correlation analysis. SDS were associated with tumors in the right corticospinal tract, fornix, and inferior fronto-occipital fasciculus and the left uncinate fasciculus, whereas ADS was associated with tumors in the left uncinate fasciculus and first segment of the superior longitudinal fasciculus and the right temporal cingulum and thalamus using Bayesian regression analyses. ADS occurs even more frequently in patients with diffuse glioma than does SDS, which is explained partly by tumor location. This research aids the understanding of gliomas and mood dysfunction in general.

9 November 2025 in Neuro-Oncology
Verified
Journal Article
Open access
MGMaxine Gorter
Maxine Gorter
JRJantine G Röttgering
Jantine G Röttgering
VBVera Belgers
Vera Belgers
MBMarieke E C Blom
Marieke E C Blom
BTBrigit Thomassen
Brigit Thomassen
MKMartin Klein
Martin Klein
Abstract Background: While severe fatigue is common in patients with diffuse glioma, no evidence-based treatment is currently available. The objective of this RCT was to evaluate the efficacy of blended cognitive behavioral therapy (bCBT) for severe fatigue. Methods: Severely fatigued patients (Checklist Individual Strength, fatigue-severity subscale [CIS-fatigue] ≥ 35) with diffuse glioma and stable disease were randomized to 12 weeks of bCBT or a waiting list condition (WLC). The primary endpoint was fatigue severity 2 weeks after intervention. This Bayesian adaptive trial included prespecified interim analyses for efficacy at n = 40, 50, 60, 70, and 80. Secondary outcomes—health-related quality of life (HRQoL), anxiety, future uncertainty, and depression—were assessed at 2 and 12 weeks after intervention. Results: The trial was stopped for efficacy at the first interim analysis. Of 47 patients randomized, 40 patients reached the primary endpoint (mean age 53 years, 47% female). The posterior probability that CIS-fatigue scores were lower with bCBT than with WLC was 99.94%, with a large standardized effect size (Cohen’s d) of 1.12 [95% CI: 0.43–1.81]. At 2 weeks after intervention, 68% of patients were no longer severely fatigued after bCBT, compared to 24% in WLC. At 12 weeks follow-up, fatigue was still significantly lower in the bCBT group compared to WLC (d = 1.22). bCBT also demonstrated beneficial effects (d = 0.42-1.19) on anxiety, HRQoL, and future uncertainty. Conclusions: bCBT significantly reduces fatigue and improves anxiety and HRQoL in patients with diffuse glioma. These findings enable evidence-based supportive care strategies for reducing fatigue and enhancing HRQoL in this population.

27 August 2025 in Neuro-Oncology
Verified
Journal Article
Open access
MGMaxine Gorter
Maxine Gorter
JRJantine G Röttgering
Jantine G Röttgering
VBVera Belgers
Vera Belgers
MLMarike R van Lingen
Marike R van Lingen
PHPhilip C de Witt Hamer
Philip C de Witt Hamer
MKMartin Klein
Martin Klein
Background: Glioma patients often exhibit neurocognitive deficits across multiple domains, yet studies typically assess these impairments separately. This study explores aggregated neurocognitive functioning (NCF), identifying distinct profiles and their clinical correlates. Methods: NCF in glioma patients with stable disease (≥ 2 months after treatment without clinical or radiological progression) was assessed across five domains: attention, information processing speed, verbal memory, working memory, and flexibility. We used hierarchical cluster analysis to distinguish neurocognitive profiles and replicated these profiles in an independent glioma cohort. Associations between neurocognitive profiles and clinical characteristics were examined using multinomial logistic regression. Results: Four distinct neurocognitive profiles were identified in both the study (N = 108) and the validation cohort (N = 185): a preserved, memory, processing/attention, and multi-domain profile. In both cohorts, 40% of patients exhibited impaired NCF, with deficits in at least one domain observed in 44% in the study cohort and 38% in the validation cohort. In the study cohort, tumor hemisphere and prior treatment with radiotherapy or combined radio- and chemotherapy were associated with processing/attention and multi-domain profiles. In both the cohorts, the multi-domain profile showed a weak association with self-perceived NCF. No other significant associations with patient, tumor, or treatment characteristics were observed. Conclusions: NCF in glioma patients can be classified into four reproducible neurocognitive profiles. Importantly, concurrent problems in NCF are highly prevalent. Neurocognitive profiles are associated with tumor laterality, previous oncological treatment, and self-perceived NCF, but not with other clinical characteristics.